Haleon (LON:HLN) Releases Earnings Results

Key Points

• Haleon reported earnings of GBX 8.90 ($0.12) per share for the quarter, with a return on equity of 6.54% and a net margin of 9.66%.
• Shares of Haleon traded at GBX 365.83 ($4.83) after an increase of GBX 6.33 ($0.08), with a market cap of £33.02 billion and a price-to-earnings ratio of 30.77.
• JPMorgan Chase & Co. reaffirmed an "underweight" rating on Haleon, while the Royal Bank Of Canada set a target price of GBX 370 ($4.89) for the shares.

Haleon (LON:HLN - Get Free Report) issued its quarterly earnings results on Thursday. The company reported GBX 8.90 ($0.12) earnings per share (EPS) for the quarter, Digital Look Earnings reports. Haleon had a return on equity of 6.54% and a net margin of 9.66%.

Haleon Stock Performance

Shares of LON:HLN traded down GBX 6 ($0.08) during midday trading on Tuesday, hitting GBX 349.80 ($4.65). The stock had a trading volume of 23,181,641 shares, compared to its average volume of 25,361,586. The stock has a 50 day moving average price of GBX 380.59 and a two-hundred day moving average price of GBX 385.18. The company has a current ratio of 0.84, a quick ratio of 0.93 and a debt-to-equity ratio of 53.36. The company has a market capitalization of £31.57 billion, a PE ratio of 29.42, a P/E/G ratio of 1.49 and a beta of 0.19. Haleon has a 1 year low of GBX 346.10 ($4.60) and a 1 year high of GBX 419.50 ($5.58).

Insider Activity

In other news, insider Marie-Anne Aymerich acquired 21,300 shares of the firm's stock in a transaction on Friday, May 9th. The stock was bought at an average cost of GBX 405 ($5.38) per share, with a total value of £86,265 ($114,653.11). Also, insider Blathnaid Bergin bought 6,145 shares of the company's stock in a transaction dated Friday, May 16th. The stock was bought at an average cost of GBX 404 ($5.37) per share, with a total value of £24,825.80 ($32,995.48). Insiders own 10.74% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on HLN. Royal Bank Of Canada reaffirmed a "sector perform" rating and set a GBX 370 ($4.92) target price on shares of Haleon in a research report on Thursday, July 31st. JPMorgan Chase & Co. restated an "underweight" rating on shares of Haleon in a research report on Friday.

Haleon Company Profile

Haleon LSE / NYSE: HLN is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other.